Jubilant Ingrevia Limited (NSE:JUBLINGREA) announced Q1 FY27 financial results on 22 July 2026, showing strong operational momentum. Total revenue reached Rs 1,300 crore, representing 25% year-on-year growth and a 10% sequential increase from Q4 FY26. EBITDA surged to Rs 209 crore, up 36% YoY and 22% quarter-on-quarter, while profit after tax climbed to Rs 106 crore, up 41% YoY.
Key Highlights
- Total revenue for Q1 FY27 reached Rs 1,300 crore, marking a 15-quarter high with 25% YoY and 10% QoQ growth driven by healthy volume increases and improved realizations.
- EBITDA expanded to Rs 209 crore, reflecting 36% YoY growth and 22% sequential growth, with EBITDA margin improving to 16% from 15% in Q4 FY26.
- PAT after exceptional items stood at Rs 106 crore, up 41% YoY and 22% QoQ, with PAT margin widening to 8% from 7% in the prior year period.
- Specialty Chemicals segment revenue was Rs 533 crore, up 11% YoY, with EBITDA of Rs 139 crore and margins of 26%, driven by Fine Chemicals and CDMO growth.
- Nutrition segment revenue grew to Rs 243 crore, up 36% YoY, achieving the highest EBITDA in three years at Rs 36 crore with 45% YoY growth and 15% margins.
- Chemical Intermediates segment revenue surged to Rs 524 crore, up 38% YoY and 21% QoQ, with EBITDA jumping 240% YoY to Rs 57 crore on strong demand and price escalations.
- Basic and diluted EPS increased to Rs 6.7 per share from Rs 4.7 in Q1 FY26, representing 41% YoY growth, reflecting improved profitability across the business.
About the Company
Jubilant Ingrevia Limited (NSE:JUBLINGREA) is a specialty chemicals and nutrition company headquartered in Noida with manufacturing facilities across India including locations at Gajraula, Bharuch, and Greater Noida. The company operates through three primary business segments: Specialty Chemicals (comprising Pyridine and Picolines, Fine Chemicals, and Contract Development and Manufacturing Operations), Nutrition and Health Solutions (covering human nutrition, animal nutrition, and premixes), and Chemical Intermediates. The company serves diverse end-markets including pharmaceuticals, agrochemicals, personal care, nutrition, and industrial segments, with a strong focus on contract manufacturing for global innovators and serving both domestic and international customer bases.
Announcement in Detail
Jubilant Ingrevia's board approved Q1 FY27 results on 22 July 2026, disclosing a comprehensive operational and financial performance across all business segments. The company achieved consolidated total revenue of Rs 1,300 crore in Q1 FY27, representing growth of 25% year-on-year from Rs 1,038 crore in Q1 FY26 and sequential growth of 10% from Rs 1,179 crore in Q4 FY26. This marks the highest revenue in a 15-quarter period. Consolidated EBITDA reached Rs 209 crore, reflecting growth of 36% year-on-year from Rs 153 crore in Q1 FY26 and sequential growth of 22% from Rs 172 crore in Q4 FY26, with EBITDA margin expanding to 16% from 15% in both the prior year quarter and preceding quarter.
Consolidated profit after tax after exceptional items stood at Rs 106 crore in Q1 FY27, compared to Rs 75 crore in Q1 FY26 and Rs 86 crore in Q4 FY26, representing year-on-year growth of 41% and sequential growth of 22%. PAT margin improved to 8% from 7% in the corresponding prior-year quarter. Basic and diluted earnings per share increased to Rs 6.7 per share from Rs 4.7 in Q1 FY26, representing 41% year-on-year growth, and from Rs 5.5 in Q4 FY26, reflecting 22% sequential growth.
Within the Specialty Chemicals segment, revenue reached Rs 533 crore, up 11% year-on-year and 3% sequentially, with EBITDA of Rs 139 crore and margins of 26%. The Chemical Intermediates segment delivered the strongest growth with revenue of Rs 524 crore, up 38% year-on-year and 21% sequentially, driven by strong volume growth and improved realizations with effective cost pass-through. EBITDA in this segment surged to Rs 57 crore, up 240% year-on-year and 163% sequentially. The Nutrition and Health Solutions segment grew to Rs 243 crore revenue, up 36% year-on-year and 6% sequentially, with EBITDA of Rs 36 crore representing the highest in three years, up 45% year-on-year and 12% sequentially, with margins improving to 15%.
Impact on Investors
Investors will note that Jubilant Ingrevia's Q1 FY27 results demonstrate accelerated operational momentum across all three business segments, with both revenue and EBITDA expanding at rates significantly above the company's historical trends. The year-on-year EBITDA growth of 36% combined with a 100-basis-point margin expansion to 16% indicates improved operational leverage and pricing power across the portfolio. The substantial growth in the Chemical Intermediates segment, where EBITDA surged 240% year-on-year, reflects the company's ability to capture margin expansion through effective cost pass-through in an inflationary environment. The strong performance in specialty chemicals, particularly in Fine Chemicals and CDMO operations, alongside strong nutrition segment growth of 36% year-on-year, suggests diversification benefits and reduced cyclical exposure. The filing shows that earnings per share increased 41% year-on-year to Rs 6.7, providing clear accretion to shareholder value in the period.
The disclosed capital allocation priorities include ongoing investment in capacity expansion, with the multi-purpose plant remaining on track for commissioning by end of calendar year 2026, which management expects will strengthen the CDMO and fine chemicals growth roadmap. Management commentary references a pipeline of 100-plus molecules in the CDMO and fine chemicals segment with peak revenue potential of Rs 3,500 crore or more, with 25-plus confirmed molecules expected to drive growth in coming years. Investors should note that the company targets Rs 100 crore in lean savings during FY27 as part of its Pinnacle Vision operational excellence program. The acquisition and integration of Remidex Pharma has been completed, and the company reports encouraging traction from tier-one human nutrition customers. Investors will observe that the company's return on capital employed has improved given the revenue growth outpacing capex deployment in the reported quarter, though the full impact of the new multipurpose plant capex will unfold across coming quarters.
Sector / Market Context
India's specialty chemicals sector continues to benefit from structural tailwinds including rising global demand for differentiated chemical inputs, the shift of contract manufacturing to India-based CDMO players, and India's growing footprint in high-value fine chemicals and active pharmaceutical ingredients. According to data from various industry bodies, India accounts for approximately 7-8% of global pharmaceutical active pharmaceutical ingredient capacity, with the specialty chemicals subset growing at 8-10% compound annual rates over recent years. The agrochemical and nutrition segments referenced in Jubilant Ingrevia's filing align with broader government initiatives to strengthen agricultural productivity and food security. The company's investments in semiconductor-grade chemicals reflect the broader Indian government push to develop domestic semiconductor ecosystem capabilities, with various electronics and semiconductors manufacturing incentive schemes driving localization opportunities for chemical suppliers.
Global pricing dynamics for pyridine derivatives, choline products, and niacinamide have shown firming trends in recent quarters following supply-side constraints and improved demand visibility, which aligns with Jubilant Ingrevia's commentary on improved realizations across segments. The company's diversified customer base spanning pharmaceuticals, personal care, nutrition, agrochemicals, and industrial segments provides natural hedges against cyclical demand in any single end-market. The CDMO and fine chemicals growth trajectory, which the company projects will be a key driver for FY27, reflects global innovators increasingly outsourcing non-core manufacturing to specialized Indian players, particularly following supply chain diversification priorities evident post-2020.